NRXS Stock Analysis: Buy, Sell, or Hold?
NRXS - Neuraxis, Inc.
$7.87
-0.48 (-5.75%)
▼
5d:
-4.02%
30d:
+6.93%
90d:
+60.29%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When NRXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NRXS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NRXS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NRXS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NRXS is currently trading at $7.87, which is considered fair relative to its 30-day fair value range of $7.17 to $8.31.
Technical Outlook: Technically, NRXS is in a strong uptrend. Immediate support is located at $7.50, while resistance sits at $9.33. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NRXS is in a strong uptrend. Immediate support is located at $7.50, while resistance sits at $9.33. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.17 -
$8.31
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 39.8% below Wall St target ($11.00)
Trading Range Analysis
30-Day Trading Range
$7.17 -
$8.31
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.50
Resistance Level
$9.33
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-131.17
Wall Street Target
$11.00
(+39.8%)
Revenue Growth (YoY)
27.2%
Profit Margin
-218.6%
Share & Embed Analysis
Last updated: May 18, 2026 6:16 AM ET
Data refreshes hourly during market hours. Next update: 7:16 AM
Data refreshes hourly during market hours. Next update: 7:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXS showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian Allen Carrico
BUY
8060 shares
2026-04-01
Thomas Joeseph Carrico
BUY
667 shares
2026-04-01
Timothy Robert Henrichs
BUY
7593 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
